JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Search

Quidel Corp

Fechado

12.6 2.02

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.37

Máximo

12.6

Indicadores-chave

By Trading Economics

Rendimento

602M

-131M

Vendas

24M

724M

Margem de lucro

-18.062

Funcionários

6,500

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+63.53% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-498M

712M

Abertura anterior

10.58

Fecho anterior

12.6

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de mai. de 2026, 23:47 UTC

Ganhos

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3 de mai. de 2026, 22:35 UTC

Ganhos

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3 de mai. de 2026, 23:32 UTC

Ganhos

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3 de mai. de 2026, 23:20 UTC

Conversa de Mercado

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3 de mai. de 2026, 23:16 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

3 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3 de mai. de 2026, 22:20 UTC

Ganhos

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3 de mai. de 2026, 22:08 UTC

Ganhos

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3 de mai. de 2026, 22:05 UTC

Ganhos

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3 de mai. de 2026, 22:05 UTC

Ganhos

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3 de mai. de 2026, 22:05 UTC

Ganhos

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3 de mai. de 2026, 22:04 UTC

Ganhos

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3 de mai. de 2026, 22:03 UTC

Ganhos

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3 de mai. de 2026, 22:03 UTC

Ganhos

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3 de mai. de 2026, 22:02 UTC

Ganhos

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3 de mai. de 2026, 22:02 UTC

Ganhos

NAB 1H Cash Earnings A$2.64B>NAB.AU

3 de mai. de 2026, 22:02 UTC

Ganhos

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3 de mai. de 2026, 22:01 UTC

Ganhos

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3 de mai. de 2026, 22:01 UTC

Ganhos

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3 de mai. de 2026, 22:01 UTC

Ganhos

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3 de mai. de 2026, 15:06 UTC

Ganhos

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

63.53% parte superior

Previsão para 12 meses

Média 20.67 USD  63.53%

Máximo 30 USD

Mínimo 15 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

3

Manter

1

Vender

Informação Financeira

Custos administrativos e de venda

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

Resultado Operacional

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat